Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
FDA selected seven participants from 80+ requests using a scoring rubric emphasizing supply need, facility development stage, time-to-market, and manufacturing innovation. Amneal will make sterile ...
A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
Proposed 100% tariffs target branded pharma imports, with a July 31, 2026 window to negotiate onshoring agreements that could reduce the rate to 20%. Exemptions may apply through MFN-negotiated ...
Positioning shifts from treatment to prophylaxis, using vaccines to blunt antimicrobial resistance-driven unmet need and mitigate infection-associated long-term morbidity, including neurological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results